comparemela.com

Latest Breaking News On - Head of corporate brand strategy communications - Page 1 : comparemela.com

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
France
Belgium
Canada
Saclay
France-general
Italy
Toronto
Ontario
Paris
Germany
Cambridge

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition

France
Germany
China
Paris
France-general
Switzerland
Toronto
Ontario
Canada
Thailand
Belgium
Saclay

Investegate | Company Announcement

Investegate | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

France
United-states
Switzerland
Saclay
France-general
Paris
Cambridge
Cambridgeshire
United-kingdom
Shanghai
China
American

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

Toronto
Ontario
Canada
Switzerland
Saclay
France-general
France
Germany
Israel
Belgium
Paris
Cambridge

Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam

Shanghai
China
United-states
Paris
France-general
France
Saclay
Italy
Cambridge
Cambridgeshire
United-kingdom
Germany

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.